Cramer’s Analyst Says Eli Lilly’s GLP-1 Stock Rally Has Years Left to Run

Eli Lilly (LLY) posted a blowout quarter, and Mad Money says the GLP-1 drugmaker's stock story is far from over.

Jim Cramer and CNBC analyst Jeff Marks called Eli Lilly and Nvidia top momentum stocks.

Why Eli Lilly's GLP-1 Stock Still Has Room to Run

The comment came during a viewer question about how price targets get set. Cramer raised Eli Lilly and Nvidia's runs specifically when asking about the process.

Marks, the CNBC Investing Club's portfolio analyst, said stocks like these need a longer time horizon than most.

"Stocks like that you also have to look out years out in advance, too. Especially in the case of Eli Lilly, where it's more of towards the end of the decade is where it's GLP-1 sales."

- Jeff Marks, CNBC Investing Club portfolio analyst, on Mad Money

Eli Lilly's second-quarter results back that framing. Revenue hit $23 billion, up 48% year over year. A 60% jump in sales volume offset a 13% drop in realized prices.

Management raised full-year revenue guidance to a range of $85 billion to $87 billion. Mounjaro sales rose 91% to $9.9 billion worldwide. Zepbound's U.S. revenue grew 44% to $4.9 billion.

… Continue reading the full article at the original source below.